Activating the frontal brain in schizophrenia: comparison of aripiprazole versus resperidone using functional magnetic resonance imaging

Activating the frontal brain in schizophrenia: comparison of aripiprazole versus resperidone using functional magnetic resonance imaging - MRI study on the effect of Abilify versus Risperdal

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31229

Enrollment

Registered

2007-06-26

Start date

2008-01-10

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic psychosis Schizophrenia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: People diagnozed for schizophrenia according to DSM-IV. They should not repsond to first choiche treatment or suffer from serious side effects. Besides, healthy control without high education level.

Exclusion criteria

Exclusion criteria: Subjects with a psychiatric or neurologic disease other than schizophrenia, for which they have been treated. Presence of MRI incompatible implants. For safety reasons female participants who may be pregnant will be excluded.

Design outcomes

Primary

Measure	Time frame
Difference in brain activity of the prefrontal cortex between groups with different medication. Besides accuraty and reactiontimes during task performance and severeness of positive and negative symptoms.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results